Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00531284 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
A Phase 1 study of Non-Small Cell Lung Cancer and Multiple Myeloma, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 184
- Enrollment target
- 7
- Study locations
NCT00531284 is a Phase 1 study of Non-Small Cell Lung Cancer and Multiple Myeloma that has completed, run by Amgen. The registered enrollment target is 184 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (72% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT00531284, a Phase 1 study of Non-Small Cell Lung Cancer and Multiple Myeloma, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 184 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary objectives of this Phase 1b/2 study were as follows: * Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in patients with relapsed solid tumors and in patients with relapsed and/or refractory multiple myeloma and in patients with refractory lymphoma. * Phase 2 (Bolus): To evaluate the overall response rate (ORR) after 4 cycles of carfilzomib in patients with relapsed solid tumors.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
Study Locations (7)
Arizona
- Pinnacle Oncology - Scottsdale
California
- Tower Cancer Research Foundation - Beverly Hills
Illinois
- Northwestern University - Chicago
Maryland
- University of Maryland Greenebaum Cancer Center - Baltimore
New Jersey
- Hackensack University Medical Center - Hackensack
Tennessee
- The Sarah Cannon Research Institute - Nashville
Texas
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2007-09 |
| Est. Completion | 2017-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00531284
The ClinicalTrials.gov registry entry for NCT00531284 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (72% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT00531284 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00531284 about?
NCT00531284 is a clinical study titled "Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma". The primary objectives of this Phase 1b/2 study were as follows: * Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in patients with relapsed solid tumors and in patients with relapsed and/or refractory multiple myeloma and in patients with refractory lymphoma. ...
What is the current status of trial NCT00531284?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 184 participants. The study started on 2007-09. Estimated completion is 2017-05-22.
What conditions does trial NCT00531284 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Multiple Myeloma, Ovarian Cancer, Lymphoma, Solid Tumors.
What interventions are being tested in trial NCT00531284?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT00531284?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00531284 being conducted?
This trial has 7 study locations across Arizona, California, Illinois, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.